en · de · es · fr · pt
faq-desk.peptides6579.com › Data › Background And Development — Hands-On Walkthrough

Background And Development — Hands-On Walkthrough

By Editorial Desk · published 2026-07-24 · last reviewed 2026-08-01 · Data

Everything below concerns BDNF expression. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Development

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

化学性质与分析表征

从分子层面看,Semax 是线性七肽,没有二硫键、糖基或脂链修饰,N 端为游离氨基,C 端为游离羧基。分子含组氨酸与谷氨酸侧链,因此在水和甲醇等极性溶剂中溶解良好,在非极性溶剂中溶解有限。计算分子量约为 814 Da,与其质子化离子的质荷比吻合,可用于质谱确认。

稳定性主要由水解与氧化两条路径支配。肽键在中性或弱酸性条件下相对稳定,遇到强碱或长时间高温则明显断裂;甲硫氨酸侧链容易被氧化成亚砜,使主峰前移并拉低实际含量。金属离子、光照和反复冻融会进一步促进降解或聚集。冻干粉在低温避光条件下可存放较长时间,配制后的水溶液通常需要冷藏并尽快用完。

Semax at a glance

PropertyValueNotes
Molecular classSynthetic heptapeptideAnalog of an ACTH fragment
Amino acid lengthSeven residuesMet-Glu-His-Phe-Pro-Gly-Pro
OriginMoscow, 1980sInstitute of Molecular Genetics
Approved regionsRussia and some neighboring statesNot cleared in Western markets
Common trade namesMultiple national brandsSold as a nasal formulation

Semax Background And Mechanism

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.

The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.

Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.

Related pages on this site

Mechanism and Research Context

Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.

Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.

Semax Peptide Structure and Origin

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.

The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.

Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.

Handling, Stability, and Quality Control

Routine characterization relies on reversed-phase high-performance liquid chromatography to establish purity and on mass spectrometry to confirm molecular identity. Electrospray ionization and matrix-assisted laser desorption ionization are both used for mass verification. Amino acid analysis and peptide mapping can detect sequence errors. Common impurities include truncated sequences, methionine sulfoxide formed by oxidation, and deamidated products. Chromatograms are usually recorded near 214 nm, where the peptide backbone absorbs, and purity is reported as the percentage area of the principal peak.

Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.

Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.

Notes from published material

to improve glycemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycemic control. when already being treated with metformin and saxagliptin and dapagliflozin.

There is an obvious similarity between use of molecular or phenotypic data in the field of cladistics and analyses of morphological characters using a substitution model. However, there has been a vociferous debate in the systematics community regarding the question of whether or not cladistic analyses should be viewed as "model-free". The field of cladistics (defined in the strictest sense) favor the use of the maximum parsimony (MP) criterion for phylogenetic inference. Many cladists reject the position that maximum parsimony is based on a substitution model and (in many cases) they justify the use of parsimony using the philosophy of Karl Popper. However, the existence of "parsimony-equivalent" models (i.e., substitution models that yield the maximum parsimony tree when used for analyses) makes it possible to view parsimony as a substitution model. Even when maximum parsimony is used to construct a tree, substitution models can still play a role in checking the statistical validity of a tree. An example is Sun et al. (2018), where the majority-rule consensus of MP trees is annotated with Bayesian posterior probabilities under the Mk model.

In manufacturing, the simulated moving bed (SMB) process is a highly engineered process for implementing chromatographic separation. It is used to separate one chemical compound or one class of chemical compounds from one or more other chemical compounds to provide significant quantities of the purified or enriched material at a lower cost than could be obtained using simple (batch) chromatography. It cannot provide any separation or purification that cannot be done by a simple column purification. The process is rather complicated. The single advantage which it brings to a chromatographic purification is that it allows the production of large quantities of highly purified material at a dramatically reduced cost. The cost reductions come about as a result of: the use of a smaller amount of chromatographic separation media stationary phase, a continuous and high rate of production, and decreased solvent and energy requirements. This improved economic performance is brought about by a valve-and-column arrangement that is used to lengthen the stationary phase indefinitely and allow very high solute loadings to the process. In the conventional moving bed technique of production chromatography the feed entry and the analyte recovery are simultaneous and continuous, but because of practical difficulties with a continuously moving bed, the simulated moving bed technique was proposed.

Sources: en.wikipedia.org

Further detail

Following a Round 22 61-point demolition at the hands of lower-placed Hawthorn, Thompson's job was under immense pressure. After a very public review of the club, it was decided that Thompson should keep his job as senior coach. After a shaky start to the 2007 season that led many supporters to believe that nothing had changed from the 2006 season, Thompson led Geelong to a massive 15 match winning streak (the biggest in a single season in club history) and a 106-point win against the Kangaroos in the Qualifying Final which is the 5th biggest finals winning margin in AFL/VFL history. The 2007 season then culminated in one of the biggest, if not the best highlight of Thompson's career, in both a coaching and footballer's role. Thompson coached Geelong to win the AFL premiership in the 2007 AFL Grand Final by more than 100 points, which was the highest winning margin in Grand Final history, against Port Adelaide Football Club at the MCG on 29 September. It was the club's first premiership since 1963, the year of Thompson's birth. After the Essendon Football Club decided not to give Thompson's former mentor, Kevin Sheedy, a renewal of contract, there was speculation that Mark Thompson would take up the senior coaching role at Essendon for the 2008 season. However, with trade week quickly approaching, the club instead appointed Matthew Knights to the position. After Geelong's record-breaking win in the grand final, Geelong under Thompson were red hot favourite to repeat their 2007 success in the 2008 season and their form during the year did nothing to change that.

==== Release phase ==== The final stage in the life cycle of a virus is the release of completed viruses from the host cell, and this step has also been targeted by antiviral drug developers. Two drugs named zanamivir (Relenza) and oseltamivir (Tamiflu) that have been recently introduced to treat influenza prevent the release of viral particles by blocking a molecule named neuraminidase that is found on the surface of flu viruses, and also seems to be constant across a wide range of flu strains.

== Animal studies == Several studies have shown acute peripheral administration of PYY3-36 inhibits feeding of rodents and primates. Other studies on Y2R-knockout mice have shown no anorectic effect on them. These findings indicate PYY3-36 has an anorectic (losing appetite) effect, which is suggested to be mediated by Y2R. PYY-knockout female mice increase in body weight and fat mass. PYY-knockout mice, on the other hand, are resistant to obesity, but have higher fat mass and lower glucose tolerance when fed a high-fat diet, compared to control mice. Thus, PYY also plays a very important role in energy homeostasis by balancing food intake. PYY oral spray was found to promote fullness. Viral gene therapy of the salivary glands resulted in long-term intake reduction.

Sources: en.wikipedia.org

Background from the literature

Note that in the context of metal-ligand complex formation, the equilibrium constants for the formation of metal complexes are usually defined as association constants. In that case, the equilibrium constants for ligand protonation are also defined as association constants. The numbering of association constants is the reverse of the numbering of dissociation constants; in this example

=== Development === The project started with producer Mace Neufeld, and was intended as a prestige thriller headlined by James Caan but that version stalled due to difficulties with the script. Neufeld later partnered with Moshe Diamant to pitch it, under the title Heart of Stone, to football player and aspiring actor Brian Bosworth. Diamant's Epic Productions had formed a joint venture with Michael Douglas and Rick Bieber's Stonebridge Entertainment called the Stone Group and the Douglas connection was an added incentive to Bosworth. Joining the other executive producers was Gary Wichard, Bosworth's personal manager who had spearheaded his transition to movies. Producer duties were entrusted to Yoram Ben Ami, CEO of Triumph Releasing, a Columbia Pictures subsidiary that usually dealt with Diamant's product. During pre-production, the screenplay was attributed to Walter Doninger and Howard Cushnir (the latter is absent from the final credits). It was retooled for Bosworth, who consulted with the writers over about one year. A late pre-production report claimed that the story was to be set in the Midwest. However, Ben Ami indicated that the Deep South region had been chosen because it was in the script, and some of the eventual locations had been in talks to host since at least summer 1989.

Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an enzyme that in humans is encoded by the ERAP1 gene. This M1 zinc aminopeptidase is involved in the antigen processing and presentation pathway. ERAP1 is mainly located in the endoplasmic reticulum (ER), where it trims peptides at their N-terminus, adapting them for presentation by MHC class I molecules (MHC-I).

=== Neuronal Control === The most well studied is through the action of extra-pancreatic glucose sensors, including neurons found in the brain, which exert control over the alpha cells in the pancreas. The pancreas is controlled by both the sympathetic nervous system and the parasympathetic nervous system, although the method these two systems use to control the pancreas appears to be different. Sympathetic control of the pancreas appears to originate from the sympathetic preganglionic fibers in the lower thoracic and lumbar spinal cord. According to Travagli et al. "axons from these neurons exit the spinal cord through the ventral roots and supply either the paravertebral ganglia of the sympathetic chain via communicating rami of the thoracic and lumbar nerves, or the celiac and mesenteric ganglia via the splanchnic nerves. The catecholaminergic neurons of these ganglia innervate the intrapancreatic ganglia, islets and blood vessels..." The exact nature of the effect of sympathetic activation on the pancreas has been difficult to discern. However, a few things are known. It appears that stimulation of the splanchnic nerve lowers plasma insulin levels possibly through the action of α2 adrenoreceptors on beta cells. It has also been shown that stimulation of the splanchnic nerve increases glucagon secretion. Both of these findings together suggest that sympathetic stimulation of the pancreas is meant to maintain blood glucose levels during heightened arousal. Parasympathetic control of the pancreas appears to originate from the Vagus nerve.

Sources: en.wikipedia.org

Frequently asked questions

Where was Semax developed?

It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.

Is Semax an approved medication anywhere?

It is registered as a medicine in Russia and has been used clinically there for decades. No regulatory agency in Western Europe or North America has approved it for any indication.

What is the relationship to ACTH?

Semax corresponds to the four-to-ten fragment of adrenocorticotropic hormone. Because it omits the first three residues, it lacks the adrenal-stimulating action of the full hormone.

用什么方法确认分子量?

电喷雾或基质辅助激光解吸电离质谱是常用手段,测得的质子化离子质荷比可换算为分子量。结果与理论值落在合理误差内,才支持结构一致的判断。

Network